Last reviewed · How we verify
Saizen® B
Saizen B is a recombinant human growth hormone used to treat growth hormone deficiency.
Saizen B is a recombinant human growth hormone used to treat growth hormone deficiency. Used for Growth hormone deficiency in children.
At a glance
| Generic name | Saizen® B |
|---|---|
| Also known as | r-hGH, Somatropin |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Growth hormone |
| Target | Growth hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the production of insulin-like growth factor 1 (IGF-1), which promotes growth and development in children with growth hormone deficiency. Saizen B is administered via injection and is available in a variety of formulations to suit different patient needs.
Approved indications
- Growth hormone deficiency in children
Common side effects
- Injection site reaction
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? (PHASE4)
- Observational Prospective Study on Patients Treated With Norditropin®
- Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects
- An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
- r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial (PHASE1)
- Saizen in Intra-uterine Growth Retardation (PHASE3)
- Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saizen® B CI brief — competitive landscape report
- Saizen® B updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI